Pancreatic Cancer | Specialty

Dr Goel on the Future of an Exosome-Based Liquid Biopsy Plus the Biomarker CA19-9 to Detect Early-Stage Pancreatic Cancer

January 24th 2025

Ajay Goel, PhD, AGAF, discusses upcoming clinical studies examining the prognostic biomarker CA19-9 plus an investigational exosome-based liquid biopsy for the detection of early-stage pancreatic cancer.

IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer

January 20th 2025

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer

January 17th 2025

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

January 16th 2025

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

EMA Grants Orphan Medical Product Designation to Elraglusib in Advanced PDAC

January 11th 2025

An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

December 17th 2024

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

December 4th 2024

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

Tumor Treating Fields Plus Chemotherapy Improves OS in Unresectable Pancreatic Cancer

December 2nd 2024

First-line use of TTFields plus gemcitabine and nab-paclitaxel improved OS vs chemotherapy in unresectable, locally advanced pancreatic adenocarcinoma.

CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC

December 2nd 2024

CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.

Targeted Therapies Remain Central to Ongoing Research in Pancreatic Cancer

November 30th 2024

Suneel Kamath, MD, shares insights on targeted therapies in pancreatic cancer after an X Takeover with OncLive during Pancreatic Cancer Awareness Month.

Dr Kamath on the Rise in Incidence of Pancreatic Cancer

November 27th 2024

Suneel Kamath, MD, discusses the rising incidence of pancreatic cancer during Pancreatic Cancer Awareness Month.

Pancreatic Cancer Awareness Month Brings Attention to Growing Incidence and Treatment Advances

November 27th 2024

Suneel Kamath, MD, took to the OncLive X (Twitter) account during Pancreatic Cancer Awareness Month to share the importance of recognizing this disease.

Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.

Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.

The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer

November 22nd 2024

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs

November 22nd 2024

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

November 17th 2024

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.